Graded Prognostic Assessment for GI Cancer (GI-GPA)
The GI‑GPA is a diagnosis‑specific prognostic index that estimates survival in patients with gastrointestinal cancer who develop brain metastases 1 [Level I evidence].
Indications for Use
Used for adults with gastrointestinal primary tumors presenting with brain metastases to estimate prognosis and guide treatment intensity. Based solely on Karnofsky Performance Status, which strongly stratifies survival in GI‑origin brain metastases 1 [Level I evidence]; updated pooled data (n=6,984) confirm wide survival separation and utility for treatment selection and clinical‑trial stratification 2 [Level I evidence].
Insights & Cautions
Stratifies survival in GI‑primary brain metastases using Karnofsky Performance Status alone, with wide survival separation (≈3–17 months across GPA tiers) derived from large multi‑institutional cohorts 1 [Level II evidence]; updated datasets confirm similar ranges 2 [Level II evidence]. Use cautiously because single‑factor modeling risks oversimplification, may not capture extracranial disease burden or molecular heterogeneity, and can misestimate prognosis in modern‑therapy eras.